Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06551129 · ClinicalTrials.gov registry record
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
A clinical trial of Obstructive Hypertrophic Cardiomyopathy, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- 118
- Enrollment target
- 1
- Study location
NCT06551129: Recruiting study of Obstructive Hypertrophic Cardiomyopathy, sponsored by Bristol-Myers Squibb.
NCT06551129 is a study of Obstructive Hypertrophic Cardiomyopathy that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 118 participants, below the 648-participant average among 3 other Obstructive Hypertrophic Cardiomyopathy trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06551129, a study of Obstructive Hypertrophic Cardiomyopathy, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- 118 participants
- Enrollment target
- 1
- Study location
Study Summary
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.
Conditions Studied
Interventions
- DRUG Mavacamten
Study Locations (1)
Massachusetts
- Analysis Group Inc. - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2024-05-10 |
| Est. Completion | 2027-06-30 |
What NCT06551129 shows while recruiting
NCT06551129 is an observational study that tracks outcomes without assigning an intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, below the 648-participant average among 3 other Obstructive Hypertrophic Cardiomyopathy trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Obstructive Hypertrophic Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which Mavacamten is the first listed.
NCT06551129 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06551129 about?
NCT06551129 is a clinical study titled "Real-world Patient Reported Outcomes Among Patients Treated With Camzyos". This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.
What is the current status of trial NCT06551129?
This trial is currently recruiting. The enrollment target is 118 participants. The study started on 2024-05-10. Estimated completion is 2027-06-30.
What conditions does trial NCT06551129 study?
This clinical trial studies the following conditions: Obstructive Hypertrophic Cardiomyopathy.
What interventions are being tested in trial NCT06551129?
The interventions under investigation include: Mavacamten (DRUG).
Who is sponsoring clinical trial NCT06551129?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06551129 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obstructive Hypertrophic Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
RECRUITING
-
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
RECRUITING
-
Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI